i3 Pharmaceuticals is a pharmaceutical manufacturing company that offers selegiline HCl, ranolazine ER, and solid oral drug products.
i3 Pharmaceuticals has raised $16.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2022.
i3 Pharmaceuticals is headquartered in Warminster, United States.
i3 Pharmaceuticals is a pharmaceutical manufacturing company that offers selegiline HCl, ranolazine ER, and solid oral drug products.
i3 Pharmaceuticals is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"i3 Pharmaceuticals — Funding & Investors." VCBacked, May 23, 2022, https://www.vcbacked.co/company/i3-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2022). i3 Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/i3-pharmaceuticals
{{cite web |title=i3 Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/i3-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated